Stanford University HIV Drug Resistance Database - A curated public database designed to represent, store, and analyze the divergent forms of data underlying HIV drug resistance.

Essential Data on NRTI DRMs

Last updated on 2016-6-20

Prevalence of NRTI DRMs in ARV-naive and -treated patients and their contributions to reduced NRTI susceptibility
DRM HIVDB
Score
SDRM Prevalence (%) Phenotypic Fold Resistance
ARV-Naive
(n=65026)
ARV-Treated
(n=26974)
3FTC
(n=1361)
ABC
(n=1267)
AZT
(n=1373)
TDF
(n=1081)
M184V
60
0.2
53
>50
3
0.3
0.5
L74V
60
0.01
9
1.0
1.5
0.3
0.6
K65R
60
0.03
5
5
3
0.8
2
L74I
60
0.02
4
0.8
1.2
0.8
0.8
Q151M
60
0
3
1.7
4
5
1.1
Y115F
60
0.01
2
1.4
3
4
1.7
M184I
60
0.04
2
>50
1.7
0.3
0.6
V75T
60
0
1
1.8
1.6
0.8
0.9
T69i
45
0
0.9
3
5
18
4
T215Y
40
0.02
27
1.5
1.8
6
1.4
T215F
40
0.01
10
1.5
1.7
8
1.6
K70R
30
0.06
18
1.3
1.3
5
1.7
T69D
30
0.03
6
1.1
1.0
0.8
0.9
V75M
30
0.03
3
0.9
1.3
1.4
1.1
V75A
30
0.02
0.5
NA
NA
NA
NA
V75S
30
0
0.2
NA
NA
NA
NA
T69d
30
 
0
0.2
NA
NA
NA
NA
K65N
30
 
0.02
0.1
NA
NA
NA
NA
D67d
30
 
0
0.09
NA
NA
NA
NA
Q151L
30
 
0
0.09
NA
NA
NA
NA
K70d
30
 
0
0.03
NA
NA
NA
NA
S68d
30
 
0
0
NA
NA
NA
NA
T215I
20
0.03
1
1.8
1.5
5
1.6
T215S
20
0.3
0.9
0.8
0.8
0.3
0.7
T215C
20
0.08
0.7
0.9
1.0
1.2
0.8
T215V
20
0.01
0.6
1.1
1.0
1.7
1.0
T215D
20
0.2
0.6
1.3
0.8
0.3
0.6
T215N
20
 
0.02
0.2
NA
NA
NA
NA
T215A
20
 
0.1
0.2
NA
NA
NA
NA
T215E
20
0.1
0.2
2
1.1
1.2
1.3
T215L
20
 
0.05
0.1
NA
NA
NA
NA
M41L
15
0.3
29
1.1
1.1
2
1.5
D67N
15
0.05
27
1.2
1.2
2
1.2
L210W
15
0.06
18
1.2
1.4
4
1.6
K70E
15
0.02
0.7
2.0
1.1
0.2
1.0
K70G
15
 
0
0.4
1.4
1.2
0.3
1.1
K70T
15
 
0.03
0.3
0.1
0.9
3
1.8
K70N
15
 
0.03
0.3
1.0
1.3
1.6
1.4
K70Q
15
 
0.02
0.2
NA
NA
NA
NA
K70S
15
 
0
0.1
NA
NA
NA
NA
K219Q
10
0.08
11
1.1
1.0
0.9
1.0
K219E
10
0.02
6
1.0
0.9
0.4
0.8
K219N
10
0.03
3
1.2
1.1
1.1
1.0
K219R
10
0.07
3
1.8
1.6
3
1.5
D67G
10
0.04
2
1.1
1.1
2
1.2
F116Y
10
0
2
1.1
1.0
3
1.2
F77L
10
0.1
2
1.0
0.9
4
1.4
D67E
10
0.01
0.5
1.2
1.5
1.0
1.5
K219W
10
 
0
0.3
NA
NA
NA
NA
D67S
10
 
0
0.2
NA
NA
NA
NA
D67H
10
 
0
0.2
NA
NA
NA
NA
T69G
10
 
0
0.2
NA
NA
NA
NA
D67T
10
 
0
0.2
NA
NA
NA
NA
K65E
10
 
0.02
0.1
NA
NA
NA
NA
A62V
5
 
0.8
5
0.9
1.0
1.2
1.2
V75I
5
 
0.04
3
1.5
1.1
1.8
0.9

    Footnotes:
  1. HIVDB Score: The highest score for 3TC (lamivudine), ABC (abacavir), AZT (zidovudine), and TDF (tenofovir). The HIVDB scores for 3TC and FTC (emtricitabine) are identical.
  2. SDRM (Surveillance Drug Resistance Mutation): Nonpolymorphic DRMs that have been used for TDR surveillance (Bennett DE et al. PLoSOne 2009).
  3. Without Major DRMs: Primary DRMs are more likely to occur without additional DRMs. However, many co-occurring DRMs have primary roles in conferring resistance to different ARVs. For example, several primary NRTI DRMs usually occur in combination with M184V because M184V develops rapidly in patients with virological failure while receiving a 3TC or FTC-containing regimen.
  4. Phenotypic Fold Resistance: The contribution of each DRM to reduced NRTI susceptibility (fold increase in the NRTI concentration required to inhibit a fixed virus inoculum by 50%) determined using published regression analyses. All results are based on susceptibility tests performed using the PhenoSense assay (Monogram, South San Francisco). The complete dataset used for the regression analyses is downloadable (HIVDB Genotype-Phenotype Dataset, http://hivdb.stanford.edu/cgi-bin/GenoPhenoDS.cgi). Phenotypic data for FTC do not differ significantly from the phenotypic data for 3TC. Red: Large contribution to reduced in vitro susceptibility. Pink: Statistically significant modest contribution to reduced in vitro susceptibility. Negative values indicate contribution to increased in vitro susceptibility.